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Dr Michael Stoner (Greenville, NC). Today, Dr Moore and
his colleagues examined the NIS [National Inpatient Sample] data
set to examine trends in vena caval filter placement. And what we
saw here was that a prophylactic filter seemed to outpace a thera-
peutic filter by the criteria established by the authors. There are a
variety of reasons for this that are speculated within themanuscript,
including divergent provider mix, mixed professional societal rec-
ommendations, and of course, financial and economic gain. In fact,
as one of my partners likes to point out, vena caval filter placement
is the best-paid 15 minutes in vascular surgery.
With that inmind, and within the context of cost-containment
and health care economics, I think that that makes this presenta-
tion very important. I have a few questions and comments for the
author. First of all, from the NIS data set, can we glean any efficacy
information regarding filter placement, especially in those patients
undergoing prophylactic filter placement? As you point out in the
manuscript and in the presentation, a great deal of money was
spent placing the filters, and my question is: Was this money well
spent?
Second, can you provide me any more insight about the
prophylactic filter group of patients? Specifically, I’d like to know if
there was an increase in the severity of medical illness or comor-
bidities over time that would account for this increased resource
utilization. If your logistic regression model corrected for this,
then this may simply be expanded indications.
And you raise the point that there is an increased incidence of
DVT [deep venous thrombosis] and PE [pulmonary embolism]
seen over time, and this may be part of increased imaging resource
utilization as well. We may simply be finding more occult venous
thrombotic pathology. Again, is there any indication in the NIS
data set that these were increased rates related to increasingly sicker
hospital population, or were these rates correlated with other
diagnoses or procedures? If not, then I would say that your
hypothesis in the manuscript is correct and that this is merely a
by-product of imaging over-utilization that is so common today.
And lastly, my question for you is sort of an open-ended one:
Where do we go from here? You point out that more and more
filters are being placed and that one of the principal driving forces
for this is the prophylactic indication. And this is often driven by
rather weak or soft indications. A randomized control trial to
better define these indications would be cumbersome and may notrequired. That leaves us essentially with societal recommendations
and even government and third-party payor payment restrictions.
I’d like to know what your thoughts are about this.
Dr Moore. In regards to your question about efficacy, the
NIS, unfortunately, does not allow us to answer a question like
that. You couldn’t tell from NIS data if a patient had a pulmonary
embolus before or after they had a filter placed, because it is just
discharge data and the timeline is not specified. So unfortunately,
that question really can’t be answered from the NIS.
As far as more insight into the prophylactic filter group, we
made an attempt to look at that group by cross-referencing them
with a large number of diagnoses and procedure codes that either
increase the risk of thromboembolic disease or make its prophylaxis
difficult. Interestingly, about 10% of prophylactic filters that were
placed were placed without any of those diagnoses or procedure
codes. And so then the question is, “Why was that filter placed?”
But again, the limitations of the NIS make it difficult to tell if this
is a sicker hospital population compared to one 10 years ago.
As far as cost-containment, I agree, a prospective multicenter
trial evaluating this would be very difficult. In order to have
enough events, PEs or PE-related deaths to determine if this is
helping people, you would need a large number of people. Unfor-
tunately, a large number of these prophylactic filters are placed in
trauma patients who are often difficult to follow-up. So I agree that
it would be a very difficult study to conduct, but we need to make
a strong effort at answering the question before somebody else
answers it for us for the purposes of cost-containment.
Dr VikramKashyap (Cleveland, Ohio). Beautiful snapshot of
what is happening with caval filters. My question is, can you tell us
howmany of these were removed? And perhaps the strategy would
be to find out which of these patients came back for secondary
hospitalization and had the code for removal of a foreign body.
DrMoore.One of the downsides to the NIS is that you can’t
track a patient over time. This could be one of the explanations for
why the DVT and PE diagnoses increased. If one patient gets
hospitalized 5 times during that year and has the diagnosis code of
DVT each time, it is going to get counted as five different DVTs.
For the same reason, it is impossible to track a patient to see if they
came back to get a filter removed.
Nevertheless, we did look at the removal code and it did not
change over time. Approximately 6000 foreign bodies were re-
moved each year during the study period, but it is a generic foreign
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different things. Likewise, you can’t tell if a filter is retrievable or
permanent with NIS data.
Dr Jeffrey Rhodes (Rochester, NY). In one of your slides
toward the end, the diagnosis of filter and pulmonary embolus
combined seemed to drop over the last few years. So even though
there was an increase of prophylactic filter use. It looked like there
was a similar decrease in pulmonary embolus. I guess my question
is: Is that correct?
Dr Moore. I think the slide you are referring to is the one
showing the proportion of vena caval filters that are therapeutic or
prophylactic. The proportion of all vena caval filters that are placed
in combination with pulmonary embolus has actually dropped.
Dr Rhodes. So the question is, although there is a higher
percentage, the absolute number of prophylactic filters has gone
up, and likewise, the number of pulmonary emboli has gone down.
When you figure your cost data, you need to figure out what the
cost of a PE is, because those prophylactic filters may actually be
functional.
The other thing is from a DRG (Diagnosis Related Group)
standpoint, if they have a DVT or pulmonary embolus, I believe
that will increase the DRG. So to use cost basis on outpatient
assumptions doesn’t really give you the true cost, because there is
mind that the UK has a population one-fifth that of the USA, thisactually no more money spent, because the hospital doesn’t get
reimbursed when you have a pulmonary embolus, et cetera, unless
they up-code the DRG. Just as a comment.
Dr Moore. I agree with that. We were just trying to come up
with an estimate that we could feel good about. The cost of filter
placement in an inpatient was too variable to use for this purpose.
Dr Rhodes.No, I understand. Just to make a conclusion that
we are spending too much money, I don’t think, based on the NIS
database that you can accurately do that. That was my concern.
Dr Moore. I understand.
Dr Anil Hingorani (Brooklyn, NY). I am always concerned
about these large data sets fromNIS, or et cetera, about the validity
of the data. Were you able to validate any of this data either
internally or externally?
Dr Moore. There was a paper published in the past using the
national hospital discharge survey to examine filter placement from
1979 to 1999. They showed that it increased from 2000 filters in
1979 to 49,000 filters a year in 1999. Our estimate for 1999 was
around 52,000. That is all the validation I can offer at this time. I
agree that these large databases have some inherent limitations and
you have to take this data with a grain of salt. The absolute
numbers are probably not as important as the trends. I think the
trends are valid.INVITED COMMENTARYPhilip Coleridge Smith, London, United Kingdom
I read this article and was impressed with the efforts of the
authors in extracting data from the databases reflecting medical
practice in theUnited States of America (USA). I was exceptionally
impressed by the number of inferior vena cava (IVC) filters that are
deployed each year, a considerable contrast to medical practice in
the United Kingdom (UK). I expected, at each turn of the page, to
find some outcome data reflecting the value of this policy of
prophylactic use of IVC filters, but was profoundly disappointed
on reaching the end of the article to find no indication of the value
of investing considerable time, effort, and health care funds in
placing these devices. The authors also express scepticism about
the extent of use, especially prophylactic use, of IVC filters. The
simple question I would like the authors to answer is: How many
lives were saved? It is unfortunate that this cannot be deduced from
public domain database information.
Checking publicly available data from the Department of
Health (UK) Hospital Episode Statistics, I found that 474 patients
underwent IVC filter treatment in the UK in 2005. Bearing inamounts to a filter usage one-fiftieth of that of the USA. Even
taking into account the possibilities of coding and other errors in
these data, this reflects a huge difference in medical practice. So
perhaps our impoverished social health care system is failing the
UK population?
I then investigated publicly available information from the
World Health Organization Statistical Information System. I
checked the adult mortality rate (probability of dying between the
age of 15 and 60 years/1000 population) both sexes, for 2006.
This is 80/1000 in the UK and 109/1000 in the USA. These data
clearly do not measure the direct outcome of IVC filter placement
but certainly offer no support to the extensive use of such devices
to prevent death from pulmonary embolism in the USA.
Clinical practice in the USA in this context appears to be based
on the opinion of experts, which can be regarded as level III
evidence, rather than on randomized clinical trials. This has re-
sulted in huge expenditure without clear benefit. The use of IVC
filters deserves much more detailed research to establish their
value.
